{
    "clinical_study": {
        "@rank": "45409", 
        "acronym": "Medis", 
        "arm_group": [
            {
                "arm_group_label": "active tDCS", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "simulated tDCS", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether TDCS is an effective prophylactic therapy\n      of chronic migraine."
        }, 
        "brief_title": "Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Migraine as Defined by Criteria of International Headache Society (IHS)", 
        "condition_browse": {
            "mesh_term": [
                "Headache", 
                "Migraine Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "Consenting patients will report on a book, all of their migraine attack for 1 month. Then\n      they will be randomized to the active tDCS group or sham tDCS group. Patients will have one\n      session of tDCS per day  during the first week, then one session per week for a month and\n      finally a session every 15 days for 1 month. After tDCS sessions, patients will be followed\n      for 3 months. Throughout their participation in the study, patients will complete their\n      migraine record (1month of base line before tDCS, 2 months during tDCS, 3 months after\n      tDCS).\n\n      Patients will have 5 evaluation examinations:\n\n        -  The first, one before tDCS,\n\n        -  The second, 1 month after the beginning of tDCS\n\n        -  The  third, immediately after the end of tDCS\n\n        -  The fourth, 1 month after the end of tDCS\n\n        -  And the last one, 3 months after the end of tDCS.\n\n      The physician responsible for conducting tDCS sessions will make the randomization via a\n      website.\n\n      The physician in charge of the evaluation examinations will don't know the allocated\n      treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of chronic migraine for more than 1 year\n\n          -  Stable treatment since 1 month\n\n          -  Frequency of migraine crisis is above 8 per month during last month\n\n          -  chronic migraine that has not been improved over the previous year by at least 3\n             different prophylactic treatments recommended and well conducted\n\n          -  Patient agreeing not to try other migraine prophylactic treatment, throughout the\n             study\n\n          -  Patient's written consent\n\n        Exclusion Criteria:\n\n          -  History of drug addiction, epilepsy, or severe head trauma with bone break\n\n          -  History of psychiatric illness (psychosis and severe cognitive disorders) may\n             interfere with the proper conduct of the study\n\n          -  Presence of intracranial ferromagnetic material or an implanted stimulator\n\n          -  Introduction of a new treatment for less than a month\n\n          -  Pregnant women, parturient women, breast-feeding mother. Lack of effective\n             contraception\n\n          -  Person not understanding the study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120326", 
            "org_study_id": "DCIC13/48"
        }, 
        "intervention": [
            {
                "arm_group_label": "active tDCS", 
                "description": "The area of \u200b\u200bstimulation is determined by  by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.\nStimulation parameters:\n2 mA intensity\nContinuous stimulation for 20 min with rise times and fall times of 10 seconds each", 
                "intervention_name": "Transcranial direct current stimulation of the motor cortex", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "simulated tDCS", 
                "description": "The area of \u200b\u200bstimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.\nStimulation parameters:\nThe intensity of the stimulation current is 2 mA\nThe current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation.", 
                "intervention_name": "simulation of Transcranial direct current stimulation of the motor cortex", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Chronic migraine, tDCS, Transcranial direct current stimulation", 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "HODAJ Hasan, MD", 
                    "phone": "33 4 76 76 52 13"
                }, 
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France", 
                        "state": "Isere", 
                        "zip": "38043"
                    }, 
                    "name": "Grenoble University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "ALIBEU Jean-Pierre, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "NOELLE B\u00e9n\u00e9dicte, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "MICK Gerard, MD, PHD", 
                    "phone": "+33 4 76 67 15 15"
                }, 
                "facility": {
                    "address": {
                        "city": "Voiron", 
                        "country": "France", 
                        "state": "Isere", 
                        "zip": "38500"
                    }, 
                    "name": "Hospital of Voiron"
                }, 
                "investigator": [
                    {
                        "last_name": "MICK G\u00e9rard, MD, PHD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "RAMPINNEAU Jean-Pierre, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomised Double-blind Evaluation of the Prophylactic Efficacy of Transcranial Direct Current Stimulation (tDCS) in Chronic Migraine", 
        "overall_contact": {
            "email": "HHodaj@chu-grenoble.fr", 
            "last_name": "Hasan HODAJ, MD", 
            "phone": "+33 4 76 76 52 13"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Grenoble", 
            "last_name": "HODAJ Hasan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France : ANSM - french health product safety angency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Comparison of the evolution of seizure frequency between the two groups", 
            "safety_issue": "No", 
            "time_frame": "Evolution of seizure frequency since base line to 3 months after the end of tDCS"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120326"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Headache Impact Test 6 (HIT-6) questionnaire", 
                "measure": "Comparison of the evolution of seizure severity between the two groups", 
                "safety_issue": "No", 
                "time_frame": "Evolution of seizure severity since base line to 3 months after the end of tDCS"
            }, 
            {
                "description": "Frequency of taking crisis treatment. After each crisis, taking crisis treatment will be noted by the patient on his migraine record book.", 
                "measure": "Comparison of the evolution of crisis treatment use between the two groups", 
                "safety_issue": "No", 
                "time_frame": "Evolution of crisis treatment use since base line until 3 months after the end of tDCS"
            }, 
            {
                "description": "Migraine Disability Assessment Scale (MIDAS) scale", 
                "measure": "Comparison of the evolution of the disease impact between the two groups", 
                "safety_issue": "No", 
                "time_frame": "Evolution of the disease impact since base line to 3 months after the end of tDCS"
            }, 
            {
                "description": "Clinical Global Impression (CGI) scale", 
                "measure": "Comparison of the evolution of the patient satisfaction between the two groups", 
                "safety_issue": "No", 
                "time_frame": "Evolution of the patient satisfaction  since base line to 3 months after the end of tDCS"
            }, 
            {
                "description": "Short Form 12 (SF-12)  quality of life questionnaire", 
                "measure": "Comparison of the evolution of the quality of life between the two groups", 
                "safety_issue": "No", 
                "time_frame": "Evolution of the quality of life since base line until 3 months after the end of tDCS"
            }, 
            {
                "description": "Hospital Anxiety and Depression scale (HAD) questionnaire", 
                "measure": "Comparison of the evolution of anxiety and depression levels between the two groups", 
                "safety_issue": "No", 
                "time_frame": "Evolution of anxiety and depression levels since base line until 3 months after the end of tDCS"
            }
        ], 
        "source": "University Hospital, Grenoble", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Grenoble", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}